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Clinical and epidemiological aspects 
of streptococcus pyogenes 
pharyngitis and carriage in Africa
GAS pharyngitis through appropriate primary prevention measures 
and treating all symptomatic GAS sore throats with a course of oral 
or parenteral penicillin(8) presents the opportunity for primary 
intervention of RHD,(9) thereby reducing the economic and major 
public health consequences associated with disease burden.(10,11)
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INTRODUCTION
Infection with Group A β-haemolytic Streptococcus, a gram-positive 
bacterium also known as Streptococcus pyogenes, results in muco-
sal and skin diseases such as pharyngitis and pyoderma.(1) While 
most cases of sore throat are due to viral infections such as influenza 
and require symptomatic treatment before eventually self-resolving, 
group A streptococcal pharyngitis specifically refers to a sore throat 
resulting from an infection with group A streptococcus (GAS). 
Following the initial infection, or after repeated GAS pharyngeal 
and skin infections, more serious GAS-related illnesses may result 
(Table 1) such as acute post-streptococcal glomerulonephritis, 
acute rheumatic fever (ARF) and rheumatic heart disease (RHD).(2-5) 
RHD is associated with significant morbidity and mortality in 
children and young adults living in developing countries. 
In South Africa, guidelines for the management of pharyngitis 
(including bacterial tonsillitis) are provided in various Depart-
ment of Health publications.(6,7) Clinical features suggestive of 
β-haemolytic streptococci group A are sore throat, inflamed tonsils 
with exudate, tender and enlarged cervical lymph nodes and often, 
a sudden onset of fever as illustrated in Table 2. The current 
standard of care targets children aged 3 - 15 years for primary 
prevention, i.e. patients presenting with a sore throat are treated 
with penicillin if there are no signs of viral infection. Addressing 
Infection with Group A β-haemolytic Streptococcus, also 
known as Streptococcus pyogenes, results in various mucosal 
and skin diseases including pharyngitis. An exaggerated 
immune response to a single or repeated group A strep-
tococcal (GAS) infection subsequently results in acute 
rheumatic fever (ARF) and, in the absence of intervention, 
repeated bouts of ARF may in turn result in progression to 
RHD, particularly in those ARF patients with cardiac 
involvement. Addressing GAS pharyngitis through appro-
priate primary prevention measures and treating all symp-
tomatic GAS sore throats with a course of oral or parenteral 
penicillin presents an opportunity for the primary inter-
vention of RHD. Failure to eradicate streptococci from the 
pharynx occurs in about one third of non-treated cases, 
giving rise to carrier status in those individuals harbouring 
intracellular GAS and thus representing a potential source of 
the acquisition of infections for other children and adults. 
Improved living conditions and access to healthcare during 
the last century are credited for the considerable decline in 
the prevalence of ARF and RHD in developed countries. 
However, a few studies have been reported from within 
Africa, and in these GAS carriage ranged around 9.0%. In 
South African studies GAS carriage isolation rates, which 
range from 1.62% to16.8%, were reported. As regards the 
prevalence of GAS pharyngitis, it is generally higher in 
developing countries and impoverished communities within 
industrialised nations. The most-up-to-date data from South 
Africa was collected more than 30 years ago with rates then 
ranging from 23.2% to 45.5%. There are no incidence data 
on GAS pharyngitis in Africa.
This review found that there is a need to document the 
epidemiology of GAS carriage and GAS pharyngitis in 
school children of all ages within Africa. Molecular charac-
terisation of strains harboured in the pharynx of carriers and 
of those isolated during bouts of pharyngitis, will help to 
identify risk factors associated with carriage in school-aged 
children and infl uence the planning and evaluation of man-
agement programmes in the screening of pharyngeal carriers 
and treatment of GAS pharyngitis.  SAHeart 2013;10:434-439
 
435
A
ut
um
n 
20
13
Vo
lu
m
e 
10
 •
 N
um
be
r 2
Failure to eradicate streptococci from the pharynx occurs in about 
one third of non-treated cases, giving rise to the carrier status in 
those individuals harbouring intracellular GAS.(12) Carriers of GAS 
may represent a potential source for the acquisition of infections 
for other children and adults. A longitudinal study over 44 months 
demonstrated the persistence of carrier strains during repeated 
episodes of GAS infection in 50% of participants.(13) Thus, GAS 
carriage reflects the reservoir of circulating strains, which are 
relevant to disease, such as pharyngitis.
In culture, Streptococcus pyogenes can be differentiated from 
normal throat flora by their distinct appearance as β-haemolytic 
colonies on 5% sheep agar incubated under anaerobic conditions 
(Figure 1). β-haemolytic streptococci can further be differentiated 
into serotypes using the Lancefield grouping system including, for 
example, GAS which is distinguished by its group A carbohy-
drate.(2,14) Earlier work by Rebecca Lancefield established a type-
specific surface antigen on GAS, the M-protein which is encoded by 
TABLE 1: Group A streptococcal-related diseases(2,5,19) 
Pharyngitis and Scarlet Fever
Pyoderma and Streptococcal Skin Infections
Invasive Streptococcal Disease: 
Streptococcal Toxic Shock Syndrome
Necrotizing Fasciitis
Septicaemia
Post-Infectious Sequelae
Rheumatic fever 
Acute post-streptococcal glomerulonephritis 
Reactive arthritis 
PANDAS
PANDAS = Paediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal infections.
TABLE 2: South African Essential Drug List: Diagnosis and Treatment of streptococcal infection in children aged 3 - 15 years.(6)
Difficulty in swallowing 
liquids or open mouth
Hoarseness longer 
than 3 weeks
Obstructive symptoms, 
e.g. stridor, greyish 
membrane of tonsils
Tonsils red 
± follicies, fever
Runny nose cough 
hoarse voice
Viral pharyngitis
Streptococcal 
throat
More than 4 episodes 
chronic condition not 
responding
chronic cervical 
lymphadenopathy
Refer
Refer
Refer
Refer
Refer
YES
YES
YES
ReferYES
YES YES
NO
NO
NO
NO
NO
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FIGURE 1: Pattern of haemolysis around streptococcal colonies distinguishing beta (A) with large zones of complete haemolysis around 
colonies from alpha (B) with its incomplete haemolysis and dark green agar under the colonies.  Photo:  M Engel, 2012
A B
FIGURE 2: In vitro percentage killing in human whole blood 
Percentage killing by bactericidal antibodies evoked by the 30-valent vaccine.  A. Vaccine serotypes.  B.  Non-vaccine serotypes. Courtesy of J. Dale.
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the emm gene and is the major target for the immune system.(15) 
Recent advances in molecular biology have made it possible to 
differentiate the more than 200 variations in the emm sequence by 
so-called emm typing.(16,17) The N-terminal region of the M-protein 
is the target for vaccine development, having been shown to evoke 
antibodies with the greatest bactericidal activity, while showing 
no cross-reaction with human tissues.(18) Amino acid sequences of 
M proteins of 30 emm types have been included in the latest 
vaccine initiative and preliminary results indicate bactericidal killing 
of >40% in over 90% of the vaccine serotypes and additional cross-
opsonic activity against 60% of 40 non-vaccine serotypes of GAS 
evaluated (Figure 2).
EPIDEMIOLOGY OF ASYMPTOMATIC 
PHARYNGEAL CARRIAGE 
Asymptomatic children can be a major reservoir of pharyngeal 
GAS. A pooled GAS carriage prevalence of 12% (95% CI: 9% - 14%) 
in healthy children aged 5 - 17 years was reported in a recent 
review of 18 clinic- and school-based studies on streptococcal 
carriage in both industrialised and developing countries.(20) Amongst 
the 7 studies on school-aged children included in the review, the 
prevalence of asymptomatic carriage ranged from 10% in Sweden 
to 21% in Iran. In another 16 month follow-up study conducted in 
community-based family medicine practices in Australia, seasonal 
carriage rates ranged from 8% - 16% amongst 160 randomly selected 
families,(21) while in a prospective surveillance study conducted over 
9 months in Fiji, a GAS carriage of 6.0% was observed amongst 685 
healthy children.(22) 
Results from India show contrasting figures; in Chennai, 8.4% of 
1 102 school children from overcrowded government or charity-
aided schools in slum-like conditions harboured GAS(23) while in a 
rural community in Northern India, a prevalence rate of only 1.3 % 
was observed in 3 385 children aged 5 - 15 years.(24) Still within 
the region, a cross-sectional study across 4 schools in Nepal, 
isolated GAS from 10.9% of 350 students 5 - 15 years of age.(25) 
Elsewhere, in Grenada, a study conducted in randomly selected 
schools observed a GAS prevalence of 5.2% among 1 388 children 
aged 5 - 15 years.(26)
Data on GAS carriage from countries in Africa remain scarce 
with only a few studies reporting on carriage. In Ethiopia, Abdissa 
reported a 9.7% carriage rate in pharyngeal isolates from 937 
healthy participants aged 6 - 14 years (mean age, 11 years).(27) An 
earlier study in Tunisia documented a rate of 9.0% from throat 
swabs taken from 155 controls.(28) More recently, Sadoh reported a 
prevalence of almost 10% among asymptomatic school children 
in Nigeria.(29)
In South Africa there is a dearth of recent studies on GAS carriage 
rates in school-aged children, with only 4 studies conducted more 
than 25 years ago. In a study of 12 050 school children from largely 
lower-socio economic households in Soweto, isolation rates of 
5.2% were reported with a significantly higher rate of GAS isolation 
during the winter months and a peak incidence in fifth and sixth 
school grades.(30) In another study from the northern part of South 
Africa, contrasting carriage rates of 1.62% and 16.8% were reported 
in asymptomatic Black participants from a remote traditional 
community and an urban setting respectively.(31)  In the same study, 
urban Whites had a carriage prevalence of only 3.4%. A study 
conducted in the late 1970s in the densely overcrowded Hout Bay 
community of Cape Town reported an overall prevalence of 3.6% 
amongst 1 150 children aged 6 - 17 years.(32) The 2 schools surveyed 
had respective prevalence rates of 2.4% and 12%, the latter 
speculated to be reflective of the 10km distance from the nearest 
primary health care polyclinic. Finally, a study involving mostly 
grade 3 school children of either mixed or Indian ancestry reported 
GAS carriage rates >20% in summer and <5% in spring.(33)
Few studies report on the distribution of emm types amongst 
asymptomatic GAS carriers.
In Fiji, while not reporting specific emm types, Steer et al. observed 
that 32% of GAS emm sequence types were shared between 
carriage and sore throat isolates.(22) To date, only 1 study reports 
on the distribution of emm types amongst asymptomatic GAS 
carriers in Africa, indicating diversity in M strains.(34)
EPIDEMIOLOGY OF GAS PHARYNGITIS 
GAS-positive pharyngitis is common among school-aged learners, 
with the peak age of incidence for GAS infections being between 
5 and 15 years.(35) Generally, developing countries have higher 
prevalence rates of GAS isolated from patients with pharyngitis 
compared to industrialised nations, except for impoverished popu-
lations within industrialised countries.(19) A recent review of 17 
studies of GAS prevalence calculated a pooled prevalence estimate 
of 37% among children presenting with sore throat from both 
industrialised and developing countries.(20) Of the studies included 
in the review, the prevalence rates ranged from 23% in the United 
States to 58% in a study from the Netherlands; although on closer 
inspection of the Netherlands study, the isolation of GAS was 
actually only 32%.(36) In the same review, 2 studies from developing 
countries reported rates of 45% (Sri Lanka) and 33% (Egypt/
Croatia/Brazil) respectively. 
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In a hospital-based study from Kolkata, GAS was isolated from 42 
out of 100 throat swabs from patients of all ages presenting with 
pharyngitis, with a peak incidence observed in the 5 - 15 years age 
group.(37) Elsewhere in India, a cross-sectional study comprising 
4 249 children aged 5 - 15 years from 25 randomly selected villages 
in the Panchkula district of Haryana in northern India, reported 
respective prevalence rates for βHS and GAS of 25.7% and 2.8% 
from children with pharyngitis with rates of isolation being signifi-
cantly higher in the winter months.(24) In the same study, the 
investigators observed pharyngeal βHS and GAS carriage rates of 
15.4% and 1.3% respectively.
The incidence of GAS positive pharyngitis is estimated to be 
616 million cases per year amongst all ages across the world based 
on a systematic review of population-based data using United 
Nations population data as the denominator. In more developed 
countries approximately 15% of school-aged children will suffer an 
episode of GAS pharyngitis each year, whereas in less-resourced 
countries, the incidence may be more than 5 times greater.(3) A few 
studies have documented incidence of GAS pharyngitis. Respective 
incidence rates of acute sore throat and GAS swab-positive 
pharyngitis include, in former Czechoslovakia, 8.3 and 3.9 cases per 
100 child-years,(38) Northern India, 705 and 95 cases per 100 child-
years(39) and Melbourne, Australia, 33 and 13 cases per 100 child-
years(21) as well as 162 and 14.7 cases per 100 child-years.(22)
Prevalence and incidence data on GAS pharyngitis from developing 
countries are largely lacking when compared to industrialised 
nations,(40) especially in South Africa. A study conducted in Pretoria 
over 30 years ago on 232 unselected patients who presented with 
a complaint of sore throat reported an overall prevalence of 33.2% 
with a significant difference between rates for Blacks (45.5%) and 
Whites (23.2%).(41) No variation in rates was observed by season 
and the overall background carriage rate of 165 controls was 12.1% 
(Blacks, 16.8%; Whites, 3.4%). In another study of 112 participants 
aged 2 to 19 years of age conducted during the summer months at 
a hospital serving the Black community in Bloemfontein, 42% of 
throat swabs cultured returned a positive GAS result.(42) 
DISCUSSION
Contemporary data on GAS carriage rates among asymptomatic 
school children in Africa and South Africa remain scarce, with no 
school-based studies undertaken across the complete spectrum of 
age groups. There is a need to document GAS carriage in school 
children of all ages which, together with molecular characterisation 
of strains harboured in the pharynx of carriers, will help to identify 
risk factors associated with carriage in school-aged children and 
influence the planning and evaluation of management programmes 
in the screening of pharyngeal carriers.(23) Also, knowledge of the 
pre-test probability influences assessment of the post-test proba-
bility of GAS pharyngitis, so as to minimise unnecessary diagnostic 
testing in children.(20) 
There is considerable heterogeneity amongst epidemiological studies 
on GAS pharyngitis in terms of participant selection, study setting 
and duration of enrolment. Few studies employed a passive sur-
veillance approach where participants are enrolled only at the time 
of presenting to the clinic or health facility, thereby reducing the risk 
of selection bias. Furthermore, few studies extend much beyond a 
year in duration, thus making it difficult to make conclusive 
judgements on seasonality. An understanding of the incidence of 
GAS pharyngitis in children within a local context is an important 
component of any ARF and RHD control programme.(43) Given that 
no data exist on the incidence of GAS pharyngitis among children 
with pharyngitis attending primary health care clinics in South Africa, 
a prospective surveillance study of sufficient duration (>3 years) is 
required.
Given the advancement in molecular methods to enable the 
characterisation of GAS strains through M-typing of the emm gene, 
there is a need to conduct emm strain typing on GAS isolates from 
patients presenting with pharyngitis at primary health care facilities 
in order to compare strains with those isolated from carriers.  In the 
light of recent progress towards a streptococcal vaccine(18) and 
given that asymptomatic carriers have been shown to maintain the 
carrier streptococcal strain when progressing to active disease,(13) 
identification of the DNA sequencing pattern of the 5’ hypervariable 
region of the cell-surface M-protein (so called emm typing)(44) may 
inform vaccine development and later help in assessing the impact 
of vaccination, the monitoring of serotype changes and its efficacy 
within the population.
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